Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

NovoCure (NVCR) closed the last trading session at $18.31, gaining 2.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.14 indicates a 91.9% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 47.5% increase from the current price level, the most optimistic analyst expects t ...